Furthermore, NZ-1 inhibited tumor cell-induced platelet aggregation and tumor metastasis by its neutralizing activity13, indicating that NZ-1 is a suitable candidate for molecular targeted therapy against podoplanin-expressing cancers. The gene discussed is PDPN; the disease is cancer.